<DOC>
	<DOCNO>NCT00857532</DOCNO>
	<brief_summary>The primary aim study compare regional amyloid burden Parkinson 's disease ( PD ) normal control subject . We hypothesize significant difference overall amyloid burden PD patient compare age-matched normal control .</brief_summary>
	<brief_title>Florbetapir F 18 PET Imaging Beta-amyloid Parkinson 's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Subjects may enrol ( inclusion criterion ) : Are male female â‰¥60 year age Meet research diagnostic criterion Parkinson 's disease : Diagnosis parkinsonian syndrome Bradykinesia ( slowness initiation voluntary movement progressive reduction speed amplitude repetitive action ) At least one following : muscle rigidity , rest tremor , postural instability due visual , vestibular , cerebellar proprioceptive cause Supportive criterion diagnosis PD ( two require ) Unilateral onset symptom persistent asymmetry Rest tremor present Progressive illness Excellent response levodopa dyskinesia Levodopa response 5 year Clinical course 10 year Have ability lie flat tolerate 10 minute PET scan . Subjects may enrol follow present ( exclusion criterion ) : History repeat stroke , repeat head injury , definite encephalitis Use neuroleptic onset symptom Sustained remission Strictly unilateral feature persist &gt; three year onset Significant supranuclear gaze palsy Cerebellar , pyramidal early severe autonomic finding Early severe dementia suggest diagnosis dementia Lewy body ( DLB ) Imaging study show structural abnormality could explain parkinsonism Negative response adequate levodopa trial Current clinically significant psychiatric disease prohibits provide informed consent participation study Current clinically significant endocrine metabolic disease , pulmonary , Women childbearing potential two year post menopausal surgically sterilize Have receive investigational medication , participate trial investigational medication within last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>amyloid burden</keyword>
	<keyword>Parkinson 's disease</keyword>
	<keyword>florbetapir PET</keyword>
	<keyword>amyloid PET imaging</keyword>
</DOC>